Los andes copper files promising prefeasibility study for vizcachitas copper project in chile

Los Andes Copper Ltd (TSX-V:LA) said it has filed a prefeasibility study at its Vizcachitas project l...

April 11, 2023, 9:53 am

3 consumer loan stocks to benefit from the propering industry

Recessionary fears and worsening asset quality hurt the Zacks Consumer Loans industry players. Efforts to digitize operations, decent loan demand and ...

April 10, 2023, 9:54 am

Palantir: the gift is back

Palantir warned investors in a recent blog post about piling into the AI hype train. It cautioned that possible regulatory backlash and reckoning coul...

April 9, 2023, 1:14 am

cac 40 forms a double-top as lvmh, hermes, kering stocks rallies

The cac 40 index has pulled back in the past few days as some investors start taking profits after a su...

April 5, 2023, 11:40 pm

Here's why hold strategy is apt for cactus (whd) stock now

cactus (WHD) boasts a solid margin profile. However, WHD has considerable exposure to heightened volati...

April 4, 2023, 9:10 am

China probes micron for cybersecurity risks, urges japan to stay out of u.s. chip export curbs

The U.S. and China chip battle continues to escalate. In China, the country's cybersecurity watchdog has initiated a probe into U.S. memory chip maker...

April 4, 2023, 7:39 am

Is micron in danger from u.s.-china tech bans?

U.S.-China relations continued to be contentious, and the biggest casualties continue to be businesses in both countries. Recently, there's been an in...

April 3, 2023, 11:27 am

Gossamer bio: merck's stellar data impressive, but game not over for seralutinib

Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vasc...

April 2, 2023, 4:12 am

Travere therapeutics announces interim analysis from the phase 3 protect study of filspari™ (sparsentan) in iga nephropathy published in the lancet and presented at world congress of nephrology 2023

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control SAN DIEGO, April 01, 202...

April 1, 2023, 8:30 am

Pfizer: don't bank on mrna vaccines

A huge increase in cost may reduce demand. Contradictory evidence on efficacy and safety may be a conce...

April 1, 2023, 12:55 am

Belite bio reports full-year 2022 operational highlights and financial results

12-month interim data from the ongoing 2-year, Phase 2 Stargardt disease (STGD1) study continues to show halting or slowing of lesion growth; 18-month...

March 31, 2023, 11:03 pm

Micron stock slumps as china launches cybersecurity review, but company says it stands by its product security

A spokesperson for Micron Technology Inc. MU, -4.45% said that the company is aware that the Cyberspace Administration of China has announced its inte...

March 31, 2023, 3:46 pm

European equity close: another solid day wraps up a great week and great quarter

During the height of the banking rout, the market went from bank to bank and tested each one. Credit Suisse failed but all the eurozone and UK bank...

March 31, 2023, 3:36 pm

European equities seen just slightly higher at the open today

• Eurostoxx +0.1%
• Germany DAX +0.1%
• France cac 40 +0.2%
• UK FTSE +0.1%...

  March 31, 2023, 7:19 am

Coya therapeutics to present biomarker and preliminary efficacy clinical data for coya 301 for the treatment of patients with alzheimer's disease (ad) at the 2023 keystone symposia meeting for neurode

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing ...

March 31, 2023, 7:00 am

Coya therapeutics to present biomarker and preliminary efficacy clinical data for coya 301 for the treatment of patients with alzheimer's disease (ad) at the 2023 keystone symposia meeting for neurode

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing ...

March 31, 2023, 7:00 am

Coya therapeutics to present biomarker and preliminary efficacy clinical data for coya 301 for the treatment of patients with alzheimer's disease (ad) at the 2023 keystone symposia meeting for neurode

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing ...

March 31, 2023, 7:00 am

Bitcoin advocacy group illuminates ecb, eurotower, encouraging adoption and education

The “Bitman” collective advocated for Bitcoin adoption by illuminating the ECB building with the Bitcoin logo. Read Full Story The post Bitcoin Ad...

March 31, 2023, 12:14 am

Additional detailed analyses from phase 2 study 201 of lecanemab published as three papers in peer-reviewed journals

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (...

March 30, 2023, 11:30 pm

European equity close: onto the frontburner

Closing changes for the main European bourses:

• Stoxx 600 +1.1%
• UK FTSE 100 +0.8%
• German DAX +1.3%
• French ...

  March 30, 2023, 3:37 pm